11/9/2024  1:03:18 PM Chg. -0.060 Volume Bid1:03:18 PM Ask1:03:18 PM Market Capitalization Dividend Y. P/E Ratio
140.460EUR -0.04% -
Turnover: -
140.460Bid Size: - 141.380Ask Size: - 22.36 bill.EUR - -

Business description

Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
 

Management board & Supervisory board

CEO
Jacob Thaysen, PhD
Management board
Ankur Dhingra, Steve Barnard, PhD, Nicole Berry, Todd Christian, Everett Cunningham, Scott Davies, Pat Leckman, Kevin Pegels, Carissa Rollins, Salli Schwartz, Bas Verhoef, Jakob Wedel, Gretchen Weightman, Jenny Zheng
Supervisory board
Stephen P. MacMillan, Jacob Thaysen, PhD, Frances Arnold, PhD, Caroline Dorsa, Robert S. Epstein, Scott Gottlieb, Gary S. Guthart, Anna Richo, Philip Schiller, Sue Siegel, Scott B. Ullem
 

Company data

Name: Illumina Inc.
Address: 5200 Illumina Way,San Diego, California 92122, USA
Phone: +1-858-202-4500
Fax: +1-858-202-4766
E-mail: info@illumina.com
Internet: www.illumina.com/
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 12/31
Free Float: 48.29%
IPO date: 7/28/2000

Investor relations

Name: -
IR phone: +1-858-291-6421
IR Fax: -
IR e-mail: ir@illumina.com

Main Shareholders

Others
 
56.21%
Vanguard Group
 
11.41%
BlackRock Inc.
 
8.35%
EDGEWOOD MANAGEMENT LLC
 
4.32%
State Street Corporation
 
4.22%
BAILLIE GIFFORD CO
 
3.31%
LOOMIS SAYLES CO L P
 
2.78%
HENDERSON GROUP PLC
 
2.76%
Morgan Stanley
 
2.32%
Others
 
4.31%